Renaissance Technologies LLC Acquires 48,314 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Renaissance Technologies LLC lifted its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 29.7% during the 2nd quarter, Holdings Channel reports. The firm owned 210,914 shares of the company’s stock after purchasing an additional 48,314 shares during the quarter. Renaissance Technologies LLC’s holdings in MaxCyte were worth $827,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MXCT. Cadian Capital Management LP bought a new stake in MaxCyte during the fourth quarter worth $26,531,000. Chevy Chase Trust Holdings LLC lifted its stake in shares of MaxCyte by 2,182.6% in the 1st quarter. Chevy Chase Trust Holdings LLC now owns 1,296,397 shares of the company’s stock valued at $5,432,000 after acquiring an additional 1,239,602 shares during the last quarter. Swedbank AB bought a new stake in shares of MaxCyte in the 1st quarter valued at about $6,704,000. Blair William & Co. IL lifted its stake in shares of MaxCyte by 7.3% in the 1st quarter. Blair William & Co. IL now owns 273,064 shares of the company’s stock valued at $1,144,000 after acquiring an additional 18,501 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in MaxCyte during the 1st quarter valued at approximately $174,000. Institutional investors own 68.81% of the company’s stock.

Insider Buying and Selling

In other MaxCyte news, Director Stanley C. Erck sold 21,607 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the sale, the director now directly owns 269,118 shares of the company’s stock, valued at $998,427.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Thomas M. Ross sold 15,476 shares of MaxCyte stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $4.54, for a total value of $70,261.04. Following the completion of the transaction, the executive vice president now owns 25,000 shares in the company, valued at approximately $113,500. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the transaction, the director now owns 269,118 shares of the company’s stock, valued at approximately $998,427.78. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,850 shares of company stock valued at $307,148. 3.00% of the stock is owned by company insiders.

MaxCyte Price Performance

MXCT opened at $3.78 on Tuesday. MaxCyte, Inc. has a one year low of $2.77 and a one year high of $5.55. The firm has a market capitalization of $396.23 million, a price-to-earnings ratio of -10.80 and a beta of 1.39. The business has a 50 day simple moving average of $4.11 and a two-hundred day simple moving average of $4.24.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. The company had revenue of $10.43 million for the quarter, compared to the consensus estimate of $8.20 million. During the same quarter in the prior year, the business posted ($0.10) EPS. As a group, sell-side analysts expect that MaxCyte, Inc. will post -0.44 EPS for the current fiscal year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.